250 related articles for article (PubMed ID: 22160379)
21. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
22. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Jones K; Nourse J; Corbett G; Gandhi MK
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e169-74. PubMed ID: 19196381
[TBL] [Abstract][Full Text] [Related]
23. Genipin as a novel chemical activator of EBV lytic cycle.
Son M; Lee M; Ryu E; Moon A; Jeong CS; Jung YW; Park GH; Sung GH; Cho H; Kang H
J Microbiol; 2015 Feb; 53(2):155-65. PubMed ID: 25626372
[TBL] [Abstract][Full Text] [Related]
24. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
25. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
30. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Feng WH; Cohen JI; Fischer S; Li L; Sneller M; Goldbach-Mansky R; Raab-Traub N; Delecluse HJ; Kenney SC
J Natl Cancer Inst; 2004 Nov; 96(22):1691-702. PubMed ID: 15547182
[TBL] [Abstract][Full Text] [Related]
31. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
32. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
33. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Saha B; Parks RJ
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
Shirley CM; Chen J; Shamay M; Li H; Zahnow CA; Hayward SD; Ambinder RF
Blood; 2011 Jun; 117(23):6297-303. PubMed ID: 21447826
[TBL] [Abstract][Full Text] [Related]
37. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
38. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.
Daibata M; Bandobashi K; Kuroda M; Imai S; Miyoshi I; Taguchi H
J Virol; 2005 May; 79(9):5875-9. PubMed ID: 15827204
[TBL] [Abstract][Full Text] [Related]
39. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
40. Histone Modifications as Molecular Targets in Nasopharyngeal Cancer.
Shyamasundar S; Dheen ST; Bay BH
Curr Med Chem; 2016; 23(2):186-97. PubMed ID: 26549431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
